Literature DB >> 16715490

Exocytotic release of creatine in rat brain.

Ligia S Almeida1, Gajja S Salomons, Francois Hogenboom, Cornelis Jakobs, Anton N M Schoffelmeer.   

Abstract

The guanidino compound creatine has been shown to occur throughout the brain affecting energy metabolism and mental performance and to act at central GABAA receptors as a partial agonist. Therefore, we examined the possibility that creatine may in fact represent a neuromodulator that is released in the brain in an action-potential dependent manner. To that end, we studied the uptake of [3H]creatine and its electrically evoked release from superfused rat brain slices as well as the evoked release of endogenously synthesized creatine. [3H]creatine was accumulated in neocortex slices in a Na+-dependent manner, consistent with the involvement of the Na+-dependent SLC6A8 creatine transporter. Most importantly, the electrically evoked release of [3H]creatine from neocortex slices (like that from caudate putamen and hippocampus slices) as well as the evoked release of endogenous (unlabeled) creatine was abolished when Ca2+ was omitted from the superfusion medium or in the presence of the Na+-channel blocker tetrodotoxin (TTX). Moreover, blockade of K+-channels by 4-aminopyridine (4-AP) strongly enhanced the electrically evoked release of [3H]creatine as well as that of endogenous creatine. These in vitro data indicate that creatine is not only synthesized and taken up by central neurons, but also released in an action-potential dependent (exocytotic) manner, providing strong evidence for its role as a neuromodulator in the brain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16715490     DOI: 10.1002/syn.20280

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  30 in total

1.  Sex-specific antidepressant effects of dietary creatine with and without sub-acute fluoxetine in rats.

Authors:  Patricia J Allen; Kristen E D'Anci; Robin B Kanarek; Perry F Renshaw
Journal:  Pharmacol Biochem Behav       Date:  2012-03-10       Impact factor: 3.533

2.  New insights into creatine transporter deficiency: the importance of recycling creatine in the brain.

Authors:  Jiddeke M van de Kamp; Cornelis Jakobs; K Michael Gibson; Gajja S Salomons
Journal:  J Inherit Metab Dis       Date:  2012-09-12       Impact factor: 4.982

3.  Biochemical and behavioral phenotype of AGAT and GAMT deficient mice following long-term Creatine monohydrate supplementation.

Authors:  Furhan Iqbal; Herald Hoeger; Gurt Lubec; Olaf Bodamer
Journal:  Metab Brain Dis       Date:  2017-08-14       Impact factor: 3.584

4.  Treatment by oral creatine, L-arginine and L-glycine in six severely affected patients with creatine transporter defect.

Authors:  Vassili Valayannopoulos; Nathalie Boddaert; Allel Chabli; Valerie Barbier; Isabelle Desguerre; Anne Philippe; Alexandra Afenjar; Michel Mazzuca; David Cheillan; Arnold Munnich; Yves de Keyzer; Cornelis Jakobs; Gajja S Salomons; Pascale de Lonlay
Journal:  J Inherit Metab Dis       Date:  2011-06-10       Impact factor: 4.982

5.  A new multistep induction protocol for the transdifferentiation of bone marrow stromal stem cells into GABAergic neuron-like cells.

Authors:  Shahram Darabi; Taki Tiraihi; AliReza Delshad; Majid Sadeghizadeh
Journal:  Iran Biomed J       Date:  2013

Review 6.  X-linked creatine transporter deficiency: clinical aspects and pathophysiology.

Authors:  Jiddeke M van de Kamp; Grazia M Mancini; Gajja S Salomons
Journal:  J Inherit Metab Dis       Date:  2014-05-01       Impact factor: 4.982

Review 7.  A guide to the metabolic pathways and function of metabolites observed in human brain 1H magnetic resonance spectra.

Authors:  Caroline D Rae
Journal:  Neurochem Res       Date:  2013-11-21       Impact factor: 3.996

Review 8.  Creatine metabolism and psychiatric disorders: Does creatine supplementation have therapeutic value?

Authors:  Patricia J Allen
Journal:  Neurosci Biobehav Rev       Date:  2012-03-24       Impact factor: 8.989

9.  Creatine, similarly to ketamine, affords antidepressant-like effects in the tail suspension test via adenosine A₁ and A2A receptor activation.

Authors:  Mauricio P Cunha; Francis L Pazini; Julia M Rosa; Ana B Ramos-Hryb; Ágatha Oliveira; Manuella P Kaster; Ana Lúcia S Rodrigues
Journal:  Purinergic Signal       Date:  2015-02-22       Impact factor: 3.765

10.  Arginine supplementation in four patients with X-linked creatine transporter defect.

Authors:  C Fons; A Sempere; A Arias; A López-Sala; P Póo; M Pineda; A Mas; M A Vilaseca; G S Salomons; A Ribes; R Artuch; J Campistol
Journal:  J Inherit Metab Dis       Date:  2008-10-16       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.